• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Inventiva S.A. (Amendment)

    2/9/24 4:49:38 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IVA alert in real time by email
    SC 13G/A 1 tm245335d1_sc13g.htm SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2

    (Amendment No. 3) *

       

    Inventiva S.A.

    (Name of Issuer)

     

    Ordinary Shares, nominal value €0.01 per share

    (Title of Class of Securities)

     

    46124U107
    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

      

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    ¨Rule 13d-1(c)

     

    xRule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP NO.  46124U107 Page 2 of 11 Pages

     

    1

    NAMES OF REPORTING PERSONS

     

    Sofinnova Crossover I SLP (“SC”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨

    (b) x

    3

    SEC USE ONLY 

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    France

     

     

     

     

    NUMBER OF 

    SHARES 

    BENEFICIALLY 

    OWNED BY 

    EACH 

    REPORTING 

    PERSON 

    WITH

     

    5

    SOLE VOTING POWER

     

    5,070,266 ordinary shares (including ordinary shares represented by American depositary shares); 6,110,827 voting rights, except that Sofinnova Partners SAS, a French corporation (“SP SAS”), the management company of SC, may be deemed to have sole voting power, and Antoine Papiernik (“Papiernik”), Cédric Moreau (“Moreau”), Kinam Hong (“Hong”), Joseph Anderson (“Anderson”) and Jacques Theurillat (“Theurillat”), the members of the investment committee of SC, may be deemed to have shared power to vote these shares.

    6

    SHARED VOTING POWER

     

    See row 5. 

    7

    SOLE DISPOSITIVE POWER

     

    5,070,266 ordinary shares (including ordinary shares represented by American depositary shares), except that SP SAS, the management company of SC, may be deemed to have sole voting power, and Papiernik, Moreau, Hong, Anderson and Theurillat, the members of the investment committee of SC, may be deemed to have shared power to vote these shares.

    8

    SHARED DISPOSITIVE POWER

     

    See row 7.

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,070,266 ordinary shares; 6,110,827 voting rights 

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.7% of the ordinary shares; 9.4% of voting rights 

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    OO 

           

     

     

    CUSIP NO.  46124U107 Page 3 of 11 Pages

     

    1

    NAMES OF REPORTING PERSONS

     

    Sofinnova Partners SAS, a French corporation (“SP SAS”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨

    (b) x

    3

    SEC USE ONLY 

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    France

     

     

     

     

    NUMBER OF 

    SHARES 

    BENEFICIALLY 

    OWNED BY 

    EACH 

    REPORTING 

    PERSON 

    WITH

     

    5

    SOLE VOTING POWER

     

    5,070,266 ordinary shares (including ordinary shares represented by American depositary shares); 6,110,827 voting rights. SP SAS, the management company of SC, may be deemed to have sole voting power, and Papiernik, Moreau, Hong, Anderson and Theurillat, the members of the investment committee of SC, may be deemed to have shared power to vote these shares.

    6

    SHARED VOTING POWER

     

    See row 5. 

    7

    SOLE DISPOSITIVE POWER

     

    5,070,266 ordinary shares (including ordinary shares represented by American depositary shares). SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Papiernik, Moreau, Hong, Anderson and Theurillat, the members of the investment committee of SC, may be deemed to have shared power to dispose of these shares.

    8

    SHARED DISPOSITIVE POWER

     

    See row 7. 

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,070,266 ordinary shares; 6,110,827 voting rights 

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.7% of the ordinary shares; 9.4% of voting rights 

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    OO 

           

     

     

     

    CUSIP NO.  46124U107 Page 4 of 11 Pages

     

    1

    NAMES OF REPORTING PERSONS

     

    Antoine Papiernik (“Papiernik”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨

    (b) ý

    3

    SEC USE ONLY

      

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    French Citizen

     

     

     

    NUMBER OF 

    SHARES 

    BENEFICIALLY 

    OWNED BY 

    EACH 

    REPORTING 

    PERSON 

    WITH

     

    5

    SOLE VOTING POWER

     

    5,070,266 ordinary shares (including ordinary shares represented by American depositary shares); 6,110,827 voting rights. SP SAS, the management company of SC, may be deemed to have sole voting power, and Papiernik, a member of the investment committee of SC, may be deemed to have shared power to vote these shares.

    6

    SHARED VOTING POWER

     

    See row 5. 

    7

    SOLE DISPOSITIVE POWER

     

    5,070,266 ordinary shares (including ordinary shares represented by American depositary shares). SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Papiernik, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares.

    8

    SHARED DISPOSITIVE POWER

     

    See row 7.

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,070,266 ordinary shares; 6,110,827 voting rights 

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.7% of the ordinary shares; 9.4% of voting rights 

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    IN 

           

     

     

     

    CUSIP NO.  46124U107 Page 5 of 11 Pages

     

    1

    NAMES OF REPORTING PERSONS

     

    Cédric Moreau (“Moreau”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨

    (b) x

    3

    SEC USE ONLY

      

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    French Citizen

     

     

     

     

    NUMBER OF 

    SHARES 

    BENEFICIALLY 

    OWNED BY 

    EACH 

    REPORTING 

    PERSON 

    WITH

     

    5

    SOLE VOTING POWER

     

    5,070,266 ordinary shares (including ordinary shares represented by American depositary shares); 6,110,827 voting rights. SP SAS, the management company of SC, may be deemed to have sole voting power, and Moreau, a member of the investment committee of SC, may be deemed to have shared power to vote these shares.

    6

    SHARED VOTING POWER

     

    See row 5. 

    7

    SOLE DISPOSITIVE POWER

     

    5,070,266 ordinary shares (including ordinary shares represented by American depositary shares). SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Moreau, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares.

    8

    SHARED DISPOSITIVE POWER

     

    See row 7. 

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,070,266 ordinary shares; 6,110,827 voting rights 

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.7% of the ordinary shares; 9.4% of voting rights 

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    IN 

           

     

     

     

    CUSIP NO.  46124U107 Page 6 of 11 Pages

     

    1

    NAMES OF REPORTING PERSONS

     

    Kinam Hong (“Hong”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨

    (b) x

    3

    SEC USE ONLY

      

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    U.S.A. Citizen

     

     

     

     

    NUMBER OF 

    SHARES 

    BENEFICIALLY 

    OWNED BY 

    EACH 

    REPORTING 

    PERSON 

    WITH

     

    5

    SOLE VOTING POWER

     

    5,070,266 ordinary shares (including ordinary shares represented by American depositary shares); 6,110,827 voting rights. SP SAS, the management company of SC, may be deemed to have sole voting power, and Hong, a member of the investment committee of SC, may be deemed to have shared power to vote these shares.

    6

    SHARED VOTING POWER

     

    See row 5. 

    7

    SOLE DISPOSITIVE POWER

     

    5,070,266 ordinary shares (including ordinary shares represented by American depositary shares). SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Hong, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares.

    8

    SHARED DISPOSITIVE POWER

     

    See row 7. 

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,070,266 ordinary shares; 6,110,827 voting rights 

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.7% of the ordinary shares; 9.4% of voting rights 

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    IN 

           

     

     

     

    CUSIP NO.  46124U107 Page 7 of 11 Pages

     

    1

    NAMES OF REPORTING PERSONS

     

    Joseph Anderson (“Anderson”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨

    (b) x

    3

    SEC USE ONLY

      

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    British Citizen

     

     

     

     

    NUMBER OF 

    SHARES 

    BENEFICIALLY 

    OWNED BY 

    EACH 

    REPORTING 

    PERSON 

    WITH

     

    5

    SOLE VOTING POWER

     

    5,070,266 ordinary shares (including ordinary shares represented by American depositary shares); 6,110,827 voting rights. SP SAS, the management company of SC, may be deemed to have sole voting power, and Anderson, a member of the investment committee of SC, may be deemed to have shared power to vote these shares.

    6

    SHARED VOTING POWER

     

    See row 5.  

    7

    SOLE DISPOSITIVE POWER

     

    5,070,266 ordinary shares (including ordinary shares represented by American depositary shares). SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Anderson, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares.

    8

    SHARED DISPOSITIVE POWER

     

    See row 7. 

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,070,266 ordinary shares; 6,110,827 voting rights 

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.7% of the ordinary shares; 9.4% of voting rights 

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    IN 

           

     

     

     

    CUSIP NO.  46124U107 Page 8 of 11 Pages

      

    1

    NAMES OF REPORTING PERSONS

     

    Jacques Theurillat (“Theurillat”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨

    (b) x

    3

    SEC USE ONLY

      

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Swiss Citizen

     

     

     

     

    NUMBER OF 

    SHARES 

    BENEFICIALLY 

    OWNED BY 

    EACH 

    REPORTING 

    PERSON 

    WITH

     

    5

    SOLE VOTING POWER

     

    5,070,266 ordinary shares (including ordinary shares represented by American depositary shares); 6,110,827 voting rights. SP SAS, the management company of SC, may be deemed to have sole voting power, and Theurillat, a member of the investment committee of SC, may be deemed to have shared power to vote these shares.

    6

    SHARED VOTING POWER

     

    See row 5.  

    7

    SOLE DISPOSITIVE POWER

     

    5,070,266 ordinary shares (including ordinary shares represented by American depositary shares). SP SAS, the management company of SC, may be deemed to have sole power to dispose of these shares, and Theurillat, a member of the investment committee of SC, may be deemed to have shared power to dispose of these shares.

    8

    SHARED DISPOSITIVE POWER

     

    See row 7. 

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,070,266 ordinary shares; 6,110,827 voting rights 

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.7% of the ordinary shares; 9.4% of voting rights 

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    IN 

           

     

     

     

    CUSIP NO.  46124U107 Page 9 of 11 Pages

     

    Item 1 (a).Name of Issuer: Inventiva S.A.

     

    Item 1 (b).Address of Issuer’s Principal Executive Offices: 50 rue de Dijon, 21121 Daix France.

     

    Item 2 (a).Name of Person Filing: The persons and entities filing this Amendment No. 3 to Schedule 13G are Sofinnova Crossover I SLP (“SC”), Sofinnova Partners SAS (“SP SAS”), and Antoine Papiernik (“Papiernik”), Cédric Moreau (“Moreau), Kinam Hong (“Hong”), Joseph Anderson (“Anderson”) and Jacques Theurillat (“Theurillat”), the members of the investment committee of SC (together with SC and SP SAS, the “Filing Persons”). SP SAS is the management company of SC.

     

    Item 2 (b).Address of Principal Business Office or, if none, Residence: The address of the principal place of business for each of the Filing Persons is Sofinnova Partners SAS, 7-11 boulevard Hausmann 75009 Paris, France.

     

    Item 2 (c).Citizenship: SC is a French Corporation. SP SAS is a French Corporation. Papiernik and Moreau are French citizens. Hong is a U.S.A. citizen. Anderson is a British citizen. Theurillat is a Swiss citizen.

     

    Item 2 (d).Title of Class of Securities: Ordinary shares, nominal value €0.01 per share.

     

    Item 2 (e).CUSIP Number: 46124U107

     

    Item 3.If this Statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
    (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
    (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) ¨ A non-U.S. institution, in accordance with §240.13d-1(b)(1)(ii)(J);
    (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution.

     

    Not applicable.

     

     

     

    CUSIP NO.  46124U107 Page 10 of 11 Pages

     

    Item 4. Ownership

     

    (a)Amount beneficially owned: See Row 9 of the cover page for each of the Filing Persons. The filing of this Amendment No. 3 to Schedule 13G shall not be construed as an admission by Papiernik, Moreau, Hong, Anderson and Theurillat that such person is, for the purposes of Section 13(d) of the Securities Exchange Act of 1934, the beneficial owner of any securities covered by this Statement.

     

    (b)Percent of class: See Row 11 of the cover page for each of the Filing Persons. Ownership is stated as of December 31, 2023 and the ownership percentages are based on 52,115,807 shares outstanding as of January 31, 2024, as disclosed by Inventiva S.A. on its website accordance with article 223-16 of the general regulations of the AMF (French Financial Markets Authority). Voting right percentage is based on 65,137,100 outstanding voting rights as of January 31, 2024.

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote: See Row 5 of the cover page for each of the Filing Persons.
    (ii)Shared power to vote or to direct the vote. See Row 6 of the cover page for each of the Filing Persons.
    (iii)Sole power to dispose or to direct the disposition of: See Row 7 of the cover page for each of the Filing Persons.
    (iv)Shared power to dispose or to direct the disposition of: See Row 8 of the cover page for each of the Filing Persons.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

     

    Not applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certifications.

     

    Not Applicable.

     

     

     

    CUSIP NO.  46124U107 Page 11 of 11 Pages

     

    SIGNATURE 

     

    After reasonable inquiry and to the best of the undersigneds' knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: February 6, 2024

     

    SOFINNOVA CROSSOVER I SLP   SOFINNOVA PARTNERS SAS
    By: Sofinnova Partners SAS      
             
             
    By: /s/ Antoine Papiernik   By: /s/ Antoine Papiernik
    Name: Antoine Papiernik   Name: Antoine Papiernik
    Title: Managing Partner   Title: Managing Partner
             
             
    By: /s/ Antoine Papiernik   By: /s/ Cédric Moreau
    Name: Antoine Papiernik   Name: Cédric Moreau
             
             
    By: /s/ Kinam Hong   By: /s/ Joseph Anderson
    Name: Kinam Hong   Name: Joseph Anderson
             
             
    By: /s/ Jacques Theurillat      
    Name: Jacques Theurillat      

      

     

     

     

    Get the next $IVA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IVA

    DatePrice TargetRatingAnalyst
    2/21/2025$10.00Buy
    TD Cowen
    11/12/2024$3.00Neutral
    UBS
    10/27/2023$12.00Buy
    Canaccord Genuity
    5/31/2023$11.00Buy
    ROTH MKM
    5/19/2023Sell → Buy
    Societe Generale
    3/17/2023$27.00Buy
    Stifel
    11/15/2022Buy → Sell
    Societe Generale
    11/22/2021$40.00 → $42.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $IVA
    SEC Filings

    View All

    SEC Form 6-K filed by Inventiva S.A.

    6-K - Inventiva S.A. (0001756594) (Filer)

    7/29/25 4:52:39 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Inventiva S.A.

    6-K - Inventiva S.A. (0001756594) (Filer)

    7/9/25 4:29:45 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Inventiva S.A.

    6-K - Inventiva S.A. (0001756594) (Filer)

    7/7/25 4:58:33 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

    Daix (France), New York City (New York, United States), August 11, 2025 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that Jason Campagna, MD, PhD, President of R&D and Chief Medical Officer, and David Nikodem, PhD, Vice President of US Operations will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference. The conference is being held from August 12-14, 2025, at the InterContinental Hotel in Boston, Massachusetts. During the fireside chat, Drs. Campagna and Nikodem wil

    8/11/25 4:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

    Daix (France), New York (New York, United States), July 31, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis ("MASH"), also known as non-alcoholic steatohepatitis ("NASH"), and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux. Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of June 30, 2025: Cash:

    7/31/25 4:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva Reports Preliminary 2025 First-Half Financial Information¹

    Cash and cash equivalents at €122.1 million and €24.6 million in short-term deposits2 as of June 30, 2025Revenues of €4.5 million recorded in H1 2025 Daix (France), New York City (New York, United States), July 29, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today reported certain preliminary financial results for the first half of 2025, including its cash, cash equivalents, and revenues. Preliminary Financial Results As of June 30, 2025, the Company's cash and cash equivalents amounted

    7/29/25 4:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Inventiva with a new price target

    TD Cowen initiated coverage of Inventiva with a rating of Buy and set a new price target of $10.00

    2/21/25 8:15:44 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS initiated coverage on Inventiva with a new price target

    UBS initiated coverage of Inventiva with a rating of Neutral and set a new price target of $3.00

    11/12/24 7:43:33 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Inventiva with a new price target

    Canaccord Genuity initiated coverage of Inventiva with a rating of Buy and set a new price target of $12.00

    10/27/23 7:43:43 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IVA
    Leadership Updates

    Live Leadership Updates

    View All

    Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance

    Jason Campagna, MD, PhD, joins Inventiva as President of R&D and Chief Medical Officer, succeeding Pierre Broqua, PhD, and Michael Cooreman, MDMartine Zimmermann, PharmD, joins as Executive Vice President of Regulatory Affairs and Quality AssuranceThese key leadership appointments underscore Inventiva's commitment to long-term growth and operational excellence, with topline results from NATiV3 on track for the second half of 2026 Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic

    7/9/25 4:05:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors

    Daix (France), New York City (New York, United States), June 10, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the appointment of Renée Aguiar-Lucander to its Board of Directors. The appointment was approved by shareholders at the recent Company's Annual General Meeting. Mark Pruzanski, Chairman of Inventiva: "We are thrilled to welcome Renée to the Board at this pivotal moment in Inventiva's journey. Her exceptional track record in our industry speaks for itself and will be

    6/10/25 4:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

    Inventiva secures €21.4 million leading to completion of the first tranche of the financing for c. €116 million, part of the multi-tranche equity financing of up to €348 million announced on October 14, 2024.   Proceeds from the completed first tranche to be primarily used to advance Inventiva's Phase III, NATiV3 clinical trial evaluating lanifibranor in patients with MASH.   Appointment of Mark Pruzanski as new Chairman of the Board of Directors and Srinivas Akkaraju as new member of the Board of Directors. Daix (France), New York City (New York, United States), December 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinica

    12/16/24 2:30:00 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IVA
    Financials

    Live finance-specific insights

    View All

    Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

    Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that the Board of Directors called the second tranche of its previously announced1 structured financing of up to €348 million (the "Structured Financi

    5/5/25 2:30:00 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva reports its 2024 full year results and provides a business update

    Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 millionLast patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early in January 2025 Pipeline prioritization plan presented to the workers council to focus exclusively on the development of lanifibranor, stopping all preclinical research activities and reducing the workforce by 50% Daix (France), New York City (New York, United States), March 26, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical c

    3/26/25 4:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

    Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2024 full-year financial results on Thursday, March 27, 2025. Inventiva's 2024 full-year financial results will be published on Wednesday, March 26, 2025 at 4:00 pm (New York), 9:00 pm (Paris). Frédéric Cren, CEO and cofounder

    3/19/25 4:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

    SC 13D/A - Inventiva S.A. (0001756594) (Subject)

    10/21/24 9:00:40 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

    SC 13D/A - Inventiva S.A. (0001756594) (Subject)

    10/21/24 8:54:43 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

    SC 13D/A - Inventiva S.A. (0001756594) (Subject)

    7/19/24 4:30:23 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care